Simon Ladefoged Rasmussen

Simon Ladefoged Rasmussen

Auto-generated profile, based on publicly available information

Simon Ladefoged Rasmussen

Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRSimon Ladefoged Rasmussen
Simon Ladefoged Rasmussen
HKHenrik B. Bygum Krarup
Henrik B. Bygum Krarup
KSKåre Gotschalck Sunesen
Kåre Gotschalck Sunesen
MJMartin Johansen
Martin Johansen
MSMogens Tornby Stender
Mogens Tornby Stender
OTOle Thorlacius-Ussing
Ole Thorlacius-Ussing
Colorectal cancer (CRC) is one of the most common cancers in the western world. Screening is an efficient method of reducing cancer-related mortality. Molecular biomarkers for cancer in general and CRC in particular have been proposed, and hypermethylated DNA from stool or blood samples are already implemented as biomarkers for CRC screening. We aimed to evaluate the performance of proven hypermethylated DNA promoter regions as plasma based biomarkers for CRC detection. We conducted a cross-sectional case-control study of 193 CRC patients and 102 colonoscopy-verified healthy controls. Using methylation specific polymerase chain reaction, we evaluated 30 DNA promoter regions previously found to be CRC specific. We used multivariable logistic regression with stepwise backwards selection, and subsequent leave-pair-out cross validation, to calculate the optimism corrected area under the receiver operating characteristics curve (AUC) for all stage as well as early stage CRC. None of the individual DNA promoter regions provided an overall sensitivity above 30% at a reasonable specificity. However, seven hypermethylated promoter regions (ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, and VIM) along with the covariates sex and age yielded an optimism corrected AUC of 0.86 for all stage CRC and 0.85 for early stage CRC. Overall sensitivity for CRC detection was 90.7% at 72.5% specificity using a cut point value of 0.5. Individual hypermethylated DNA promoter regions have limited value as CRC screening markers. However, a panel of seven hypermethylated promoter regions show great promise as a model for CRC detection.

8 June 2016 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
SRSimon Ladefoged Rasmussen
Simon Ladefoged Rasmussen
HKHenrik Bygum Krarup
Henrik Bygum Krarup
KSKåre Gotschalck Sunesen
Kåre Gotschalck Sunesen
IPInge Søkilde Pedersen
Inge Søkilde Pedersen
PMPoul Henning Madsen
Poul Henning Madsen
OTOle Thorlacius‐Ussing
Ole Thorlacius‐Ussing

11 May 2020 in BJS Open
Verified
Journal Article
Open access
PDF file
LSL. Schmidt Sørensen
L. Schmidt Sørensen
SRS. Ladefoged Rasmussen
S. Ladefoged Rasmussen
PCPhilip Calder
Philip Calder
MYM. Nytoft Yilmaz
M. Nytoft Yilmaz
ESE. Berg Schmidt
E. Berg Schmidt
OTO. Thorlacius‐Ussing
O. Thorlacius‐Ussing
Background This study aimed to evaluate the effect of perioperative supplementation with omega‐3 fatty acids (n‐3 FA) on perioperative outcomes and survival in patients undergoing colorectal cancer surgery. Methods Patients scheduled for elective resection of colorectal cancer between 2007 and 2010 were randomized to either an n‐3 FA‐enriched oral nutrition supplement (ONS) twice daily or a standard ONS (control) for 7 days before and after surgery. Outcome measures, including postoperative complications, 3‐year cumulative incidence of local or metastatic colorectal cancer recurrence and 5‐year overall survival, were compared between the groups. Results Of 148 patients enrolled in the study, 125 (65 patients receiving n‐3 FA‐enriched ONS and 60 receiving standard ONS) were analysed. There were no differences in postoperative complications after surgery (P = 0·544). The risk of disease recurrence at 3 years was similar (relative risk 1·66, 95 per cent c.i. 0·65 to 4·26).The 5‐year survival rate of patients treated with n‐3 FA was 69·2 (95 per cent c.i. 56·5 to 78·9) per cent, compared with 81·7 (69·3 to 89·4) per cent in the control group (P = 0·193). After adjustment for age, stage of disease and adjuvant chemotherapy, n‐3 FA was associated with higher mortality compared with controls (hazard ratio 1·73, 95 per cent c.i. 1·06 to 2·83; P = 0·029). The interaction between n‐3 FA and adjuvant chemotherapy was not statistically significant. Conclusion Perioperative supplementation with n‐3 FA did not confer a survival benefit in patients undergoing colorectal cancer surgery. n‐3 FA did not benefit the subgroup of patients treated with adjuvant chemotherapy or decrease the risk of disease recurrence.

9 January 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
SRSimon Ladefoged Rasmussen
Simon Ladefoged Rasmussen
HKHenrik Bygum Krarup
Henrik Bygum Krarup
KSKåre Gotschalck Sunesen
Kåre Gotschalck Sunesen
MJMartin Johansen
Martin Johansen
MSMogens Tornby Stender
Mogens Tornby Stender
OTOle Thorlacius-Ussing
Ole Thorlacius-Ussing
The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer

1 January 2017 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
SPSaulius Palubinskas
Saulius Palubinskas
SRSimon Ladefoged Rasmussen
Simon Ladefoged Rasmussen
True hepatic artery aneurysms (HAAs) are rare, and when complicated by gastrointestinal haemorrhage, it becomes an even rarer disease entity. The mortality is high and imaging may fail to provide the diagnosis. We present a case of a true hepatic artery aneurysm complicated by a fistula to the duodenum which was first recognised during surgery. A 77-year-old man presented with upper gastrointestinal haemorrhage. Upper endoscopy revealed an ulceration in the duodenal bulb, which was refractory to endoscopic treatment. Computed tomography and angiography did not reveal the source of haemorrhage and as such, the diagnosis was delayed, until laparotomy was performed. Resection of the HAA and graft placement resulted in complete haemostasis. True hepatic aneurysms communicating with the gastrointestinal tract have only been presented in case reports and short case series. Arteriosclerosis is a relatively common risk factor, but the underlying pathology is unknown. Meanwhile, gastrointestinal haemorrhage is a symptom of other, more common diseases in the gastrointestinal tract, and these factors, complicate the diagnostic workup. In the case of treatment refractory duodenal haemorrhage, a visceral aneurysm should be considered. Even though angiography is performed, a HAA may remain undetected due to bleeding cessation. Improved computed tomography modalities could aid in the detection of gastrointestinal haemorrhage from HAAs, and ensure timely treatment by endovascular methods or surgery if the diagnosis is kept in mind in the initial evaluation.

21 March 2025 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
SRSimon Ladefoged Rasmussen
Simon Ladefoged Rasmussen
LPLasse Pedersen
Lasse Pedersen
CTChristian Torp-Pedersen
Christian Torp-Pedersen
MRMorten Rasmussen
Morten Rasmussen
IBInge Bernstein
Inge Bernstein
OTOle Thorlacius-Ussing
Ole Thorlacius-Ussing
Objective Colorectal cancer (CRC) is the third most common cancer in Denmark, with a 5-year mortality of 40%. To reduce CRC incidence and mortality, a faecal immunochemical test (FIT)-based screening programme was introduced in 2014. Adenoma detection rate (ADR) is an established quality marker inversely associated with post-colonoscopy CRC (PCCRC), but evidence mainly stems from non-FIT populations. Using ADR in a FIT-based setting may be costly due to histopathological examination. Alternative markers like polyp detection rate (PDR) and sessile serrated lesion detection rate (SDR) could be viable but lack evidence for their association with PCCRC. Methods We conducted a nationwide cohort study of 77 009 FIT-positive participants undergoing colonoscopy (2014–2017). National registry data on CRC outcomes were linked, and endoscopy units were grouped by ADR, PDR and SDR levels. Poisson regression adjusted for age, sex and comorbidities was used to assess PCCRC risk. Results Among 70 009 colonoscopies within 6 months of FIT positivity, 4401 (92.7%) had CRC, while 342 (7.2%) were PCCRC cases. PCCRC risk was inversely associated with ADR, PDR and SDR. High ADR endoscopy units had a 35% lower PCCRC risk than low ADR units. Similar associations were found for PDR and SDR, with high SDR units showing a 33% lower PCCRC risk than low SDR units. Conclusions ADR, PDR and SDR predict PCCRC risk, with SDR emerging as a feasible, cost-efficient quality marker in FIT-based screening. This study supports SDR as a primary performance indicator in future protocols.